Please login to the form below

Not currently logged in
Email:
Password:

FDA rejects GSK and Xenoport's Horizant

GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil)

GlaxoSmithKline (GSK) and XenoPort, have received a Complete Response letter from the US Food and Drug Administration (FDA) relating to Horizant (gabapentin enacarbil), an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

The two companies submitted a New Drug Application (NDA) for Horizant extended-release tablets, to the FDA in January 2009.

The FDA's Center of Drug Evaluation and Research issue Complete Response letters once a review is completed, but when there are questions outstanding that prevent the NDA from being approved.

In the case of Horizant, the FDA indicated that a preclinical finding of pancreatic acinar cell tumours in rats was of sufficient concern to prevent approval of Horizant for RLS at this time.

GSK and Xenoport are evaluating the Complete Response letter and will communicate their intended next steps to the FDA.

Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients. Similar preclinical findings to those for Horizant were known for gabapentin when the FDA approved its use for refractory epilepsy. However, the FDA state that the 'seriousness and severity of refractory epilepsy justified the potential risks'.

Gabapentin enacarbil is also being developed in partnership with Astellas Pharma for the potential treatment of Restless Legs Syndrome in Japan. 

18th February 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics